---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-016708"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:09:01.469177+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular reports positive 52-week Phase 2b data for wet AMD therapy 4D-150

## Summary
- Phase 2b (n=30): 83% reduction in supplemental aflibercept injections (0.97 mean vs 6.0 on-label); 57% injection-free over 52 weeks.
- Recently diagnosed subgroup (n=15): 94% reduction (0.33 mean injections); 80% injection-free.
- Safety: well tolerated up to 3 years; 2.8% (2/71) 4D-150-related 1+ IOI; no hypotony, endophthalmitis, or vasculitis.
- Durable aflibercept expression up to 2 years; aqueous humor levels consistently within projected therapeutic range.
- Phase 3 trials 4FRONT-1 (Q1 2025) and 4FRONT-2 (Q3 2025) to initiate; topline 52-week data expected H2 2027.

## SEC filing metadata
- accession: 0000950170-25-016708
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017025016708/0000950170-25-016708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017025016708/fdmt-20250208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-016708
- JSON: https://secwatch.observer/filing/0000950170-25-016708.json
- Plain text: https://secwatch.observer/filing/0000950170-25-016708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.